Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

USA - English

• France - Français

AUBAGNE, France, March 29, 2022 /PRNewswire/ -- At today's combined Annual General Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of 1.26 euros per share for fiscal 2021. The total profit distributed will be 116.1 million euros. The previous year's dividend was 0.68 euros per share.

The Annual General Shareholders' Meeting has granted discharge to all directors by a large majority and approved the renewal of the appointments as Directors of Pascale Boissel, René Fáber, Lothar Kappich, Joachim Kreuzburg, and Henri Riey for a three-year term of office.

This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.

ASM documents
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/shareholders-meeting

Press images
https://www.sartorius.com/en/company/newsroom/downloads-publications

Financial calendar
April 21, 2022                      Publication of first-quarter figures (January to March 2022) 
July 21, 2022                       Publication of the first-half figures (January to June 2022)
October 19, 2022                 Publication of nine-month figures (January to September 2022)

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

Contact
Timo Lindemann
Corporate Communications Spokesman
+49 (0)551.308.4724
[email protected]
www.sartorius.com

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

SOURCE Sartorius Stedim Biotech S.A.